CDKN2A rs4846052: Understanding This Genetic Variant
The rs4846052 variant is a non-coding genetic marker located within the CDKN2A gene region on chromosome 9. It is studied for its potential associations with susceptibility to cutaneous melanoma and various common vascular health phenotypes.
What each genotype means
Baseline risk profile
This genotype represents the common version of the CDKN2A regulatory region. Research indicates this is the baseline state for this locus, and it is not associated with the increased susceptibility to melanoma or vascular phenotypes observed with the alternative allele.
This is the most common genotype in most global populations, carried by the majority of individuals.
Increased susceptibility marker
Carrying one copy of the T allele is associated with a modest increase in susceptibility to cutaneous melanoma and certain vascular phenotypes in some studies. Because this is a non-coding regulatory variant, the effect is likely subtle and influenced by many other genetic and environmental factors.
Carried by roughly 1 in 3 to 1 in 2 people of European ancestry, depending on the specific population.
Elevated susceptibility marker
Carrying two copies of the T allele is associated with a higher statistical likelihood of melanoma susceptibility compared to those without the variant. This association is based on population-level data and does not imply a direct cause of disease, as many individuals with this genotype will never develop these conditions.
Carried by approximately 4% to 9% of individuals in European populations.
What is rs4846052?
The rs4846052 variant is a single nucleotide polymorphism (SNP) situated in the 9p21.3 chromosomal region. Unlike variants that change the structure of a protein, this SNP is located in a non-coding regulatory area. This means it does not alter the amino acid sequence of the proteins produced by the nearby genes. Instead, researchers investigate such variants to see if they influence how genes are turned on or off, or how much protein is produced in specific tissues. Because it sits in a region known for complex regulatory activity, scientists use it as a marker to study how genetic architecture might influence disease susceptibility. It is important to note that being a marker does not necessarily mean the variant itself causes a disease; it may simply be inherited alongside other functional changes in the same genomic neighborhood.
The Role of the CDKN2A Gene
The CDKN2A gene is a critical tumor suppressor located at the 9p21 locus. It is unique because it encodes two distinct proteins, p16INK4A and p14ARF, which are produced through alternative splicing. These proteins play essential roles in regulating the cell cycle, effectively acting as 'brakes' that prevent cells from dividing uncontrollably. By inhibiting specific enzymes like CDK4 and CDK6, or by stabilizing the p53 protein, CDKN2A helps maintain genomic stability. When this gene functions correctly, it helps protect the body against the development of various cancers. Because of its vital role in cell cycle control, mutations that disrupt the function of CDKN2A are well-documented in familial melanoma and other cancer predisposition syndromes. Understanding the regulatory landscape around this gene, including variants like rs4846052, is a major focus of ongoing cancer research.
Research and Evidence Strength
Current research into rs4846052 characterizes it as a variant with limited or mixed evidence regarding its clinical impact. While the 9p21.3 region is widely recognized as a hotspot for both cancer susceptibility and cardiovascular health, the specific contribution of rs4846052 remains a subject of ongoing study. Large-scale genome-wide association studies (GWAS) have identified this region as being linked to various traits, but the evidence for this specific SNP is not as definitive as that for high-penetrance, rare mutations in the coding regions of CDKN2A. Because the evidence is limited, it is not currently used as a standalone diagnostic tool. Researchers continue to investigate whether this variant acts as a modifier of risk or if it is simply a bystander in a region of high genetic complexity. As with all complex traits, genetic risk is rarely determined by a single variant, but rather by the interplay of many genetic factors and environmental exposures.
What This Information Means for You
If you encounter information about the rs4846052 variant, it is important to view it within the context of current scientific understanding. This variant is a common genetic marker, not a definitive medical diagnosis. Because the evidence linking it to specific health outcomes is limited, it cannot be used to predict your personal risk of developing melanoma or vascular conditions. Genetic associations observed in large populations do not necessarily translate to individual health outcomes. You should never use this information to make medical decisions or to alter your lifestyle without consulting a healthcare professional. If you have concerns about your family history of cancer or cardiovascular disease, the most effective approach is to speak with a doctor or a genetic counselor. They can provide personalized assessments based on your complete medical history, physical exams, and established clinical risk factors, rather than relying on individual genetic markers.
How common is this variant?
The rs4846052 variant is relatively common, with a minor allele frequency typically ranging between 0.20 and 0.30 in populations of European ancestry.
Frequently asked questions
Is rs4846052 a cause of melanoma?
No, rs4846052 is a genetic marker associated with the 9p21.3 region, which is linked to melanoma risk in some studies. It is not considered a direct cause of the disease, and the evidence for its specific impact is limited.
Can I use this SNP to predict my health?
No, this SNP cannot be used to predict your health. Genetic associations are statistical findings in large groups and do not provide a reliable prediction for an individual's health outcomes.
What should I do if I have this variant?
You do not need to take any specific action. Because this is a common variant with limited evidence of clinical impact, it is not used for medical screening or clinical decision-making.
Where can I learn more about my genetic risk?
If you are concerned about your risk for specific diseases, you should consult a healthcare provider or a certified genetic counselor. They can evaluate your family history and clinical factors to provide appropriate guidance.
Sources & further reading
Educational information only, last refreshed 9/25/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4846052?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CDKN2A
Variant in the CDKN2A/B locus associated with Type 2 Diabetes risk.
Variant upstream of CDKN2A/B associated with type 2 diabetes susceptibility.
This variant is significantly associated with chronic lymphocytic leukemia risk and influences immune response pathways.